Novartis has cash for a big pharma deal—but here’s why it’s not buying

Published on 31 Jan 2025 on Invezz

Novartis AG (SWX: NOVN) has the cash to opt for a large deal in pursuit of accelerated growth – but...

Read the rest of the article

Start tracking your investments with Statfolio

CRSP beat on earnings in three of the trailing four quarters and missed the mark in the other,...

Zacks · via Yahoo Finance 3 Feb 2025

Novartis AG said profit will rise this year as new medicines help offset competition from copycat...

Bloomberg 31 Jan 2025

Novartis AG (NYSE:NVS) shares are trading higher in the premarket session on Friday. The Swiss...

Benzinga · via Yahoo Finance 31 Jan 2025

NVS' fourth-quarter earnings and sales beat estimates. Based on the strong momentum of the...

Zacks · via Yahoo Finance 31 Jan 2025

Novartis AG (SWX: NOVN) has the cash to opt for a large deal in pursuit of accelerated growth – b...

Invezz 31 Jan 2025

And with that, I will hand across to Vas. Should you invest $1,000 in Novartis Ag right now? Befo...

The Motley Fool · via AOL 31 Jan 2025

Novartis AG NVS, a Swiss pharma giant, is scheduled to report fourth-quarter 2024 and full-year...

Zacks · via Yahoo Finance 28 Jan 2025

Plus, we'll get the personal income and spending report, which includes the Fed's preferred measu...

CNBC 26 Jan 2025

Swiss luxury conglomerate Richemont’s stock market value surpassed 100 billion Swiss francs ($110...

The Business of Fashion 23 Jan 2025

(Bloomberg) -- Donald Trump opened his second term as US president with a market-jolting...

Bloomberg · via Yahoo News 21 Jan 2025